

Current Title: Assistant Professor,

Department of Gastroenterological Surgery (Surgery II),
Nagoya University Graduate School of Medicine, Nagoya, JAPAN

Personal Information:

Business Address: Nagoya University Graduate School of Medicine,
Department of Gastroenterological Surgery (Surgery II),
65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550 JAPAN

Email: m-kanda@med.nagoya-u.ac.jp

Phone: +81-52-744-2249 (work), Fax: +81-52-744-2252

Educational and Academic Experience:

1995-2001: Medical School, Nagoya University, Japan

2001: Medical Degree (MD)

2001-2003: *Internship*, Nagoya Memorial Hospital, Nagoya, Japan

2003-2007: *Resident in Surgery*, Nagoya Memorial Hospital, Nagoya, Japan

2007-2010: *Fellow in Surgery*, Nagoya University Hospital, Nagoya, Japan

2010: Doctor of Philosophy degree (PhD)

2010-2012: *Post-doctoral Fellow*, Division of Gastrointestinal Pathology, (Mentor:
Michael Goggins), Department of Pathology, Johns Hopkins Medical Institutions,
Baltimore, MD

2012-present: *Assistant Professor*, Department of Gastroenterological Surgery,
Nagoya University Graduate School of Medicine, Nagoya, Japan

Board Certification:

2007 Board Certified Surgeon; Japan Surgical Society

2009 Board Certified Surgeon in Gastroenterology; Japanese Society of Gastroenterological Surgery

2010 Board Certified Doctor in Hepatology; Japanese Society of Hepatology

Current Membership:

American Association for Cancer Research, European Society for Medical Oncology

American Society of Clinical Oncology, International Gastric Cancer Association

Awards:

2009 AACR Annual Meeting Scholar-in-Training Award (ITO-EN)

Publication Contributions:

1. **Kanda M**, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. *Gut*. 2013 Jul;62(7):1024-33.
2. **Kanda M**, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology*. 2012Apr;142(4):730-733.
3. **Kanda M**, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. *Int J Cancer*. 2016 Feb 1;138(3):721-30.
4. **Kanda M**, Fujii T, Sahin TT, et al. Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. *Ann Surg*. 2010 Mar;251(3):483-7.
5. **Kanda M**, Tanaka C, Kobayashi D, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. *Int J Cancer*. 2016 Nov 15;139(10):2290-8.
6. **Kanda M**, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. *Oncotarget*. 2016 Mar 22;7(12):13667-79.
7. **Kanda M**, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. *Br J Surg*. 2011 Feb;98(2):268-74.
8. **Kanda M**, Tanaka C, Kobayashi D, et al. Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. *Ann Surg Oncol*. 2016 Sep 6. [Epub ahead of print]
9. **Kanda M**, Shimizu D, Fujii T, et al. Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. *Int J Oncol*. 2016Sep;49(3):1195-202.
10. **Kanda M**, Fujiwara M, Tanaka C, et al. Predictive value of drain amylase content for peripancreatic inflammatory fluid collections after laparoscopic (assisted) distal gastrectomy. *Surg Endosc*. 2016 Oct;30(10):4353-62.
11. **Kanda M**, Shimizu D, Fujii T, et al. Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer. *Ann Surg Oncol*. 2016 Jun 30. [Epub ahead of print]
12. **Kanda M**, Mizuno A, Tanaka C, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. *Medicine (Baltimore)*. 2016 Jun;95(24):e3781.
13. **Kanda M**, Mizuno A, Fujii T, et al. Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. *Ann Surg Oncol*. 2016 Jun;23(6):1934-40.
14. **Kanda M**, Kobayashi D, Tanaka C, et al. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. *Gastric Cancer*. 2016 Jan;19(1):255-63.
15. **Kanda M**, Nomoto S, Oya H, et al. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. *Ann Surg Oncol*. 2016 Feb;23 Suppl 2:S214-21.